Journal List > Korean J Gastroenterol > v.58(2) > 1006844

TOOLS
Tae, Jun, Choi, Kim, Kim, Sohn, and Lee: A Case of Pegylated Interferon Alpha-2a Monotherapy in a Peritoneal Dialysis Patient with Chronic Hepatitis C
Case Report

Korean J Gastroenterol 2011;58(2):107-110.

Published online: 4 October 2011

DOI: https://doi.org/10.4166/kjg.2011.58.2.107

A Case of Pegylated Interferon Alpha-2a Monotherapy in a Peritoneal Dialysis Patient with Chronic Hepatitis C

Hye Jin Tae, Dae Won Jun, Jong Wook Choi, Woong Jun Kim, Bong Young Kim, Joo Hyun Sohn, Min Ho Lee

Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

Correspondence to: Dae Won Jun, Department of Internal Medicine, Hanyang University Medical Center, 17, Haengdang-dong, Sungdong-gu, Seoul 133-792, Korea. Tel: +82-2-2290-8338, Fax: +82-2-2290-8314, E-mail: noshin@hanyang.ac.kr

Received 5 March 201112 May 2011       Accepted 12 May 2011

Copyright © 2011 Korean Ophthalmological Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Pegylated interferon (PEG-IFN) is now the standard treatment for chronic hepatitis C. But, there are few reports about patients with end stage renal disease, and treatment protocol for HCV infection has not been determined, particularly in patients on peritoneal dialysis. We experienced a case of a peritoneal dialysis patient with chronic hepatitis C who was successfully treated with PEG-IFN monotherapy. A 50-year old man was undergoing peritoneal dialysis because of diabetic nephropathy. Considering that his HCV genotype was 2, we decided to treat him with PEG-IFN alpha-2a monotherapy 4 month after the beginning of peritoneal dialysis. We adopted a 90 μ g of PEG-IFN administration. After the injection of PEG-IFN, dialysate concentration of PEG-IFN did not change significantly. HCV-RNA disappeared at the 4th week and sustatined virus response was achieved thereafter. No side effects were observed during the treatment of 24 weeks. PEG-IFN monotherapy with dose modification may be a safe and effective treatment for HCV infection in patients undergoing peritoneal dialysis.

Keywords: Hepatitis C, Chronic, Interferons, Peritoneal dialysis

References

1. Mimura I, Ishibashi Y, Tateishi R, Kaname S, Fujita T. Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C. NDT Plus. 2008; 1:233–235.
crossref
2. Kim YJ. The management of chronic hepatitis C. Korean J Med. 2009; 77:275–281.
3. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacoki-netics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol. 2002; 42:1109–1115.
4. Liu CH, Liang CC, Liu CJ, et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut. 2009; 58:314–316.
5. Johnson DW, Dent H, Yao Q, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009; 24:1598–1603.
crossref
6. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997; 51:981–999.
crossref
7. Couchoud C. Epidemiology and financial aspects of peritoneal dialysis in end-stage renal disease. Rev Prat. 2010; 60:1194–1196.
8. Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol. 2003; 38(Suppl 1):S104–S118.
crossref
9. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008; 109:S1–S99.
10. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006; 13:316–321.
crossref
11. Uchihara M, Izumi N, Sakai Y, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron. 1998; 80:51–56.
crossref
12. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008; 48:1690–1699.
crossref
13. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006; 130:231–264.
crossref
14. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39:1147–1171.
crossref
15. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2008; 15:79–88.
crossref
16. Bruchfeld A, Ståhle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection–a pilot study. J Viral Hepat. 2001; 8:287–292.
17. Chan TM, Ho SK, Tang CS, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton). 2007; 12:11–17.
crossref
18. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of inter-feron-alpha in haemodialysis patients with HCV infection: a mul-ticentre, prospective study. Nephrol Dial Transplant. 2001; 16:1017–1023.
19. Kim HW, Choi BS, Kim MK, et al. Results of treatment of chronic hepatitis C with recombinant interferon alpha (rINF-alpha) in pre- and post-transplant patients. J Korean Soc Transplant. 2001; 15:194–202.

Fig. 1.
Mean peritoneal fluid and serum PEG-IFN concentration-time profiles following a 90 μg subcutaneous dose. PEG-IFN, Pegylated interferon.
kjg-58-107f1.tif
Table 1.
Mean Peritoneal Fluid PEG-IFN Concentration-Time Profiles Following a 90 μg Subcutaneous Dose
Time (hour) 0 24 48 72
PEG-IFN concentration (ng/mL) 147.0 151.9 141.2 133.9

PEG-IFN, Pegylated interferon.

Table 2.
Mean Serum PEG-IFN Concentration-Time Profiles Following a 90 μ g Subcutaneous Dose
Time (hour) 0 2 4 8 12 24 48
PEG-IFN concentration (ng/mL) 140.3 157.3 154.9 188.6 182.4 195.6 215.2

PEG-IFN, Pegylated interferon.

Table 3.
Baseline Characteristics of Clinical trial of IFN or PEG-IFN Patients on Chronic Hepatitits C on Peritoneal Dialysis
  Treatment IFN dose Outcome
Bruchfeld et al.16 IFN alpha-2b+ ribavirin 3 MU×3/wk Relapse
Chan et al.17 PEG-IFN alpha-2a 135 μ g Withdraw
Mimura et al.1 Kim et al.19 PEG-IFN alpha-2a IFN alpha-2a 30 μ g → 90 μ g 3 MU×3/wk SVR SVR

IFN, interferon; PEG-IFN, Pegylated interferon; SVR, sustained virological response.

TOOLS
Similar articles